GSK announces a groundbreaking $30 billion investment in the U.S. as President Trump visits the U.K. This commitment aims to enhance biopharma manufacturing and research, promising advancements in drug discovery and healthcare innovation.
Isomorphic Labs, leveraging AI breakthroughs from DeepMind, is on the brink of human clinical trials for cancer drugs. With major pharma partnerships, the future of drug design looks promising!
In a surprising turn of events, Regeneron has announced its acquisition of 23andMe for $256 million following the company's bankruptcy. The pharma giant aims to leverage 23andMe's vast customer data for drug discovery while prioritizing privacy and security.
